Amgen Inc. is facing a class action lawsuit filed by shareholders alleging that the company did not disclose significant tax liabilities, which led to artificially inflated stock prices and substantial investor losses. The U.S. government claims Amgen owes over $8 billion in back taxes, exposing the firm to severe IRS penalties. As the biotech giant confronts this legal and financial turmoil, its stock has already experienced notable declines.
“A shareholder · filed · a class action · on behalf of all persons and entities that purchased or otherwise acquired Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022”
“Amgen Inc. (AMGN) · failed to disclose · the impact of the Company's tax liability to investors”
“Amgen · has been accused of · improperly skirting U.S. tax laws”
“Amgen · was compelled to make · substantial disclosures regarding the Company’s outstanding tax liabilities to investors”
“The material omissions · caused · the price of Amgen stock to trade at artificially inflated prices”
“Investors · suffered · hundreds of millions of dollars in losses · when Amgen belatedly revealed the truth”
“Rosen Law Firm · reminds purchasers of securities of · Amgen Inc. · between July 29, 2020 and April 27, 2022”
“Amgen securities · may be entitled to · compensation · without payment of any out of pocket fees or costs”
“Amgen · owed more than · $3 billion in back taxes · for tax years 2010, 2011, and 2012”
“Amgen · owed more than · $5 billion in back taxes · for tax years 2013, 2014, and 2015”
“Amgen’s refusal to pay taxes claimed by the U.S. government · exposed the Company to · a substantial risk of severe financial penalties imposed by the IRS”
“Amgen Inc. · had a class period · July 29, 2020 – April 27, 2022”
